Takeda Pharmaceutical company profile
Company profile
Takeda Pharmaceutical has 47,029 employees and is headquartered in Chuo, Japan.
Nearly half of the sales of this Japanese drugmaker are generated in the United States, which accounts for 48.0% of revenue, while Europe and Canada add 25.4% and Japan 9.6%. The company researches, develops, manufactures and markets pharmaceutical products, and it also out-licenses them to other companies. Its portfolio covers gastroenterology, neuroscience and oncology, with brands such as Entyvio, Adcetris, Trintellix and Vyvanse, along with the QDENGA brand. Partnerships for development and commercialization include AbbVie, GSK, Ipsen and Novavax, and its sales reach Latin America, China, the rest of Asia, Russia and the Commonwealth of Independent States, the Middle East, Oceania and Africa.
In the fiscal year ended March 2026, revenue reached 4,505.7 billion yen, down 1.7% from the previous year, and the company posted a net loss of 152.4 billion yen. The group employs 47,029 people and is headquartered in Chuo, Japan, where it was founded in 1781. Its shares also trade on the New York Stock Exchange.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Japan
- Headquarters
- 1-1, Nihonbashi-Honcho 2-chome, 103-8668, Chuo
- Employees
- 47,029
- Chief executive
- Julie Kim
- Founded
- 1781
- Fiscal year
- April - March
- Listing
- 4502 · TSE
- Indices
- Nikkei 225
- Currency
- JPY
- ISIN
- JP3463000004
- Website
- takeda.com
Takeda Pharmaceutical and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Takeda Pharmaceutical4502 | Japan | $65.5B | 47,029 | 16.6% | 253.2 |
| Sun Pharmaceutical IndustriesSUNPHARMA | India | $47.86B | 47,000 | 23.3% | 41.1 |
| Jiangsu Hengrui Pharmaceuticals600276 | China | $47.82B | 20,602 | 27.4% | 35.9 |
| Divi's LaboratoriesDIVISLAB | India | $32.23B | 11,565 | 34.0% | 90.6 |
| Hansoh Pharmaceutical Group3692 | Hong Kong SAR China | $26.6B | 9,643 | 37.3% | 28.4 |
| Torrent PharmaceuticalsTORNTPHARM | India | $18.85B | 18,258 | 22.2% | 78.9 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
